PSA/IL-2/GM-CSF vaccine - Oncbiomune

Drug Profile

PSA/IL-2/GM-CSF vaccine - Oncbiomune

Alternative Names: ProscaVax; Prostatac; Prostate cancer vaccine - Oncbiomune

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oncbiomune; United States Army
  • Developer OncBioMune
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 26 Feb 2018 OncBioMune Pharmaceuticals, in collaboration with Harvard University Medical School, plans a phase II trial for Prostate cancer (Early-stage disease; First-line therapy) in 2018
  • 05 Feb 2018 OncBioMune Pharmaceuticals, in collaboration with Urology Clinics of North Texas, plans a phase II trial for Prostate cancer (Late-stage disease; Second-line therapy or greater) in USA in 2018
  • 10 Jan 2018 Updated follow-up efficacy data from a phase I trial in Prostate cancer released by OncBioMune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top